Pfizer Posts Vupanorsen Data From Mid-Stage Cardiovascular Disease Trial

Loading...
Loading...

Pfizer Inc PFE has provided an update on the Phase 2b study of vupanorsen, investigational antisense therapy for cardiovascular (CV) risk reduction and severe hypertriglyceridemia.

  • In the dose-ranging study in subjects with elevated non-HDL-C and triglycerides (TG), the study met its primary endpoint, achieving a statistically significant reduction in non-HDL-C at all doses tested at 24 weeks, compared to placebo. 
  • In addition, subjects treated with vupanorsen achieved statistically significant reductions in TG and ANGPTL3 at all dose levels at 24 weeks, compared to placebo.
  • The topline results also showed that vupanorsen dose-dependently lowered its target, angiopoietin-like 3. 
  • Pfizer is continuing to review the findings to determine the next steps regarding future development.
  • The most common adverse events were injection site reactions, which often occurred in the highest vupanorsen dose group. 
  • In November 2019, Pfizer licensed vupanorsen from Ionis Pharmaceuticals Inc IONS in a worldwide exclusive agreement. 
  • Price Action: PFE shares are down 0.45% at $50.85, while IONS stock is down 4.39% at $29 during the market session on the last check Wednesday.
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsCardiovascular diseasePhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...